CO2022014884A2 - Inmunoconjugados - Google Patents

Inmunoconjugados

Info

Publication number
CO2022014884A2
CO2022014884A2 CONC2022/0014884A CO2022014884A CO2022014884A2 CO 2022014884 A2 CO2022014884 A2 CO 2022014884A2 CO 2022014884 A CO2022014884 A CO 2022014884A CO 2022014884 A2 CO2022014884 A2 CO 2022014884A2
Authority
CO
Colombia
Prior art keywords
immunoconjugates
polypeptides
mutant interleukin
polynucleotide molecules
relates
Prior art date
Application number
CONC2022/0014884A
Other languages
English (en)
Inventor
Christian Klein
Ekkehard Moessner
Deak Laura Codarri
Laura Lauener
Anne Freimoser-Grundschober
Pablo Umaña
Cindy Schulenburg
Eleni Maria Varypataki
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2022014884A2 publication Critical patent/CO2022014884A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención se refiere en general a polipéptidos de interleucina-7 mutante, inmunoconjugados, particularmente inmunoconjugados que comprenden un polipéptido de interleucina-7 mutante y un anticuerpo que se fija a PD-1. Además, la invención se refiere a moléculas de polinucleótidos que codifican los polipéptidos de interleucina-7 mutante o los inmunoconjugados, y vectores y células huésped que comprenden dichas moléculas de polinucleótidos. La invención se refiere además a métodos para producir los polipéptidos de interleucina-7 mutante, inmunoconjugados, composiciones farmacéuticas que los comprenden, y usos de estos.
CONC2022/0014884A 2020-04-15 2022-10-19 Inmunoconjugados CO2022014884A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169510 2020-04-15
PCT/EP2021/059473 WO2021209402A2 (en) 2020-04-15 2021-04-13 Immunoconjugates

Publications (1)

Publication Number Publication Date
CO2022014884A2 true CO2022014884A2 (es) 2022-11-08

Family

ID=70289616

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014884A CO2022014884A2 (es) 2020-04-15 2022-10-19 Inmunoconjugados

Country Status (17)

Country Link
US (1) US20230192795A1 (es)
EP (1) EP4135848A2 (es)
JP (1) JP2023521238A (es)
KR (1) KR20230004494A (es)
CN (1) CN115485028A (es)
AR (1) AR121856A1 (es)
AU (1) AU2021256936A1 (es)
BR (1) BR112022020629A2 (es)
CA (1) CA3168460A1 (es)
CL (1) CL2022002751A1 (es)
CO (1) CO2022014884A2 (es)
CR (1) CR20220512A (es)
IL (1) IL294451A (es)
MX (1) MX2022012541A (es)
PE (1) PE20230111A1 (es)
TW (1) TW202200609A (es)
WO (1) WO2021209402A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230250181A1 (en) * 2021-07-09 2023-08-10 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
AU2022362681A1 (en) * 2021-10-14 2024-04-04 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
WO2023062048A1 (en) * 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
RU2437893C2 (ru) * 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2649094B1 (en) * 2010-12-10 2016-04-27 University of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
PE20140303A1 (es) 2011-02-10 2014-03-22 Roche Glycart Ag Polipeptidos interleuquina-2 mutantes
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
JP6152120B2 (ja) 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
AU2016329251B2 (en) 2015-10-02 2023-02-02 F. Hoffmann-La Roche Ag Anti-PD1 antibodies and methods of use
KR102146319B1 (ko) * 2015-10-02 2020-08-25 에프. 호프만-라 로슈 아게 Pd1 및 tim3에 특이적인 이중특이성 항체
KR20190091281A (ko) * 2016-12-13 2019-08-05 아스텔라스세이야쿠 가부시키가이샤 항인간 cd73 항체
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
SG11202005036RA (en) * 2018-01-25 2020-06-29 I Mab Biopharma Us Ltd Anti-pd-l1 antibody and il-7 fusions
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
US20220025050A1 (en) * 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
JP2022532249A (ja) * 2019-05-16 2022-07-13 アーチ オンコロジー，インコーポレイテッド インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法

Also Published As

Publication number Publication date
WO2021209402A3 (en) 2021-12-02
CN115485028A (zh) 2022-12-16
KR20230004494A (ko) 2023-01-06
AU2021256936A1 (en) 2022-07-21
US20230192795A1 (en) 2023-06-22
CR20220512A (es) 2022-11-07
BR112022020629A2 (pt) 2022-11-29
CA3168460A1 (en) 2021-10-21
WO2021209402A2 (en) 2021-10-21
IL294451A (en) 2022-09-01
CL2022002751A1 (es) 2023-05-19
TW202200609A (zh) 2022-01-01
PE20230111A1 (es) 2023-01-27
JP2023521238A (ja) 2023-05-23
MX2022012541A (es) 2022-11-07
AR121856A1 (es) 2022-07-20
EP4135848A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CO2022014884A2 (es) Inmunoconjugados
CO2019009354A2 (es) Immunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15
CO2021002907A2 (es) Constructos de anticuerpos para cldn18.2 y cd3
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
BR112018001531A2 (pt) construtos de anticorpo para cd70 e cd3
CO2021003036A2 (es) Compuestos de anillo fusionado
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
BR112019000195A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
CL2021000028A1 (es) Anticuerpo multiespecifico (divisional de solicitud 937-2020).
BR112018001638A8 (pt) construtos de anticorpo biespecífico que se ligam à mesotelina e cd3
AR053608A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
CO6341566A2 (es) Mutantes fgf21 y usos de de los mismos
CR20130314A (es) Polipéptidos interleuquina-2 mutantes
AR119338A1 (es) Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
BR112022001016A2 (pt) Métodos de produção de aflibercepte
BR112018009729A8 (pt) método para produzir um polipeptídeo recombinante, fungo filamentoso myceliophthora thermophila e uso de uma construção de ácido nucleico
BR112022008092A2 (pt) Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico
ECSP22078815A (es) Anticuerpos anti-phf-tau y usos de estos
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
BR112018010669A2 (pt) anticorpo anti-pcsk9 e utilização do mesmo
UY39699A (es) Anticuerpos anti-tau y usos de estos
BR112023021225A2 (pt) Anticorpos anti-cd20 e estruturas t car